|Day Low/High||64.05 / 65.17|
|52 Wk Low/High||60.89 / 85.97|
As is so often the case, the bears are unable to close the deal when it looks like they have an edge.
Stocks are reasonable. Or even cheap. There will be more sell-offs ahead but remember this day and do not get too negative.
I am long Merck, not Seattle Genetics, though the one to own now is obviously SGEN.
We've become accustomed lately to gap-up opens on Mondays, but some fresh acquisition agreements are helping drive this Monday's action.
The Fed's money pumping has elevated new tech, but Jay Powell and the government haven't done any favors for many other stocks.
A handful of deals have been announced this week alone and they give rise to expectations of more acquisitions to come.
6 favorite stocks and ETFs in the biotech and pharmaceutical sector, including a diversified basket of Covid-19 vaccine names.
Do these shares get back to the 2020 highs that were reached back in January?
These familiar names are displaying both technical and quantitative deterioration.
The Fed has done a lot, and is willing to do even more, but for now, is watching Congress. The fiscal side is where the next shoe falls.
Our fate is in the hands of a few dozen companies with a dizzying array of clinical trials, and whoever gets there first is gonna make a fortune.
Let's take a close look at Gilead Sciences, Regeneron and Eli Lilly.
The stock is trading above the 50-day and the 200-day moving averages.
The extent of the measures taken to combat the virus seem to be an overreaction, and no one should count on a vaccine being a magic bullet.
The RMPIA rose 3.2% for May and 3.3% for the first five months of 2020.
When I first started buying ARCT shares I didn't conceive of a valuation of $1 billion, but I also didn't conceive of the global impact of a pandemic.
I've been long Merck for a long time, since way before this pandemic became part of our lives.
GE's problem can be summarized in one sentence: The company is burning cash.
I get this rally -- it's based on more than a breaking branch this time, but there are still many uncertainties.
I'm staying long this name, and I'm staying long PFE and JNJ, and I'm staying long GILD and ABT. You know why? Because I'm optimistic.
PFE is collaborating with German drugmaker BioNTech in the effort to find a well tolerated, effective vaccine.
This contraction has been dramatic and unpredictable -- and best outcomes cannot be driven solely through economic creativity.
This is a lower probability trade, but with the coiled price action around BA, it wouldn't take much to spring this one to life.
* Mission accomplished? Sell in May and go away! * In scope and duration, stocks have rallied in a manner rarely seen in history * Month-to-date April has been the best month for equities since 1974 * The S&P Index has climbed by +31.4% since the M...
While the power of the Fed is unquestionable, there will be issues that liquidity simply can't fix.